Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.
J Surg Oncol
; 121(7): 1067-1073, 2020 Jun.
Article
in En
| MEDLINE
| ID: mdl-32153032
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Stomach Neoplasms
/
Neuroendocrine Tumors
/
Intestinal Neoplasms
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Surg Oncol
Year:
2020
Document type:
Article
Country of publication:
United States